Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.
OBJECTIVE
This report describes a positive experience of adverse event (AE) management of a multidisciplinary clinical team and 18 patients with late-stage renal cell carcinoma and hepatocellular carcinoma attending the Day Hospital Unit of the 'Centro Catanese di Oncologia Humanitas' (Italy) over a 2-year period.


METHODS
The management strategy was based on preventive measures for reducing the development of cutaneous AEs, including pain, risk of infection and patient discomfort, while avoiding the discontinuation or the reduction of the sorafenib dosage.


RESULTS
As of July 2011, eight patients were still under treatment with sorafenib; seven patients experienced cutaneous AEs and two reported severe cutaneous AEs.


CONCLUSIONS
Our treatment approach seemed to reduce the incidence and/or severity of AEs, keeping patients in treatment, which is essential for good treatment outcomes.
Day Hospital - UF Oncologia Medica, Humanitas Centro Catanese di Oncologia, via E. Dabormida 64 95126 Catania, Italy. giusy.scandurra@gmail.com
Giuseppa
G
Scandurra
Rosa Anna
RA
Aiello
Marco
M
Alì
Eleonora
E
Taibi
Maria Vita
MV
Sanò
Francesco Maurizio
FM
Todaro
Rosaria
R
La Rocca
Paolo
P
Licciardello
Michele
M
Caruso
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib